Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Jean Christophe Boyer"'
Publikováno v:
Actualités Pharmaceutiques. 61:37-40
Autor:
Nicolas Picard, Laurent Becquemont, Jean-Christophe Boyer, Vincent Haufroid, Marie-Anne Loriot, Sylvie Quaranta
Publikováno v:
Actualités Pharmaceutiques. 61:20-23
Autor:
Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, Litaty Mbatchi, André van Kuilenburg, Christine Bobin-Dubigeon, Fabienne Thomas, Etienne Chatelut, Jean-Louis Merlin, Frédéric Pinguet, Christophe Ferrand, Judith Meijer, Alexandre Evrard, Laurence Llorca, Gilles Romieu, Philippe Follana, Thomas Bachelot, Loic Chaigneau, Xavier Pivot, Véronique Dieras, Rémy Largillier, Mireille Mousseau, Anthony Goncalves, Henri Roché, Jacques Bonneterre, Véronique Servent, Nadine Dohollou, Yann Château, Emmanuel Chamorey, Jean-Pierre Desvignes, David Salgado, Jean-Marc Ferrero, Gérard Milano
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0175998 (2017)
Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The g
Externí odkaz:
https://doaj.org/article/e851b305e66844848f3f60697e611308
Autor:
Jean-Christophe Boyer, Anne-Aliénor Véry, Jean Benoît Peltier, Hervé Sentenac, Thanyakorn Rongsawat
Publikováno v:
Trends in Plant Science
Trends in Plant Science, Elsevier, 2021, 26 (1), pp.83-94. ⟨10.1016/j.tplants.2020.09.001⟩
Trends in Plant Science, Elsevier, 2021, 26 (1), pp.83-94. ⟨10.1016/j.tplants.2020.09.001⟩
International audience; Breeding new cultivars allowing reduced fertilization and irrigation is a major challenge. International efforts towards this goal focus on noninvasive methodologies, platforms for high-throughput phenotyping of large plant po
Autor:
Anaëlle Chavant, Sabine Cohen, Jérôme Guitton, Julia Tonini, Jean Christophe Boyer, Françoise Stanke-Labesque, Xavier Fonrose, Théo Willeman
Publikováno v:
Toxicologie Analytique et Clinique
Toxicologie Analytique et Clinique, Elsevier, 2020, 32, pp.253-257. ⟨10.1016/j.toxac.2020.05.002⟩
Toxicologie Analytique et Clinique, Elsevier, 2020, 32, pp.253-257. ⟨10.1016/j.toxac.2020.05.002⟩
Summary Objectives To highlight an analytical interference involving nefopam and its metabolites on urinary benzodiazepine screening with Enzyme Multiplied Immunoassay Technique (EMIT) Atellica CH from Siemens Healthineers, and to evaluate two other
Autor:
Laurence Venat-Bouvet, Melanie White-Koning, William Jacot, Alicja Puszkiel, Jacques Robert, Etienne Chatelut, Hortense Laharie-Mineur, Thomas Filleron, Valérie Le Morvan, N. Dohollou, Marc Debled, Florence Dalenc, Chantal Bernard-Marty, Alexandre Evrard, Caroline Delmas, Fabienne Thomas, Henri Roché, Jean-Christophe Boyer, Cécile Arellano, Christelle Vachoux
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1244-1255
Variations in clinical response to tamoxifen (TAM) may be related to polymorphic cytochromes P450 (CYPs) involved in forming its active metabolite endoxifen (ENDO). We developed a population pharmacokinetic (PopPK) model for tamoxifen and six metabol
Autor:
Nicolas Picard, Melody Barreau, Chantal Barin-Le Guellec, Marie-Anne Loriot, Hugo Alarcan, Sylvie Quaranta, Jean-Christophe Boyer, Laurent Becquemont
Publikováno v:
Therapies. 75:459-470
Resume La pharmacogenetique, dont les concepts sont connus depuis longtemps, est une discipline emergente en ce qui concerne son integration dans la prise en charge therapeutique des patients. Ces dernieres annees ont vu se multiplier les initiatives
Autor:
Zeinab Homayed, Gérald Lossaint, Thibault Mazard, Sophie Bravo, Jérôme Solassol, Emilie Mamessier, Jai Smith, Julie A. Vendrell, Olivia Villeronce, Marc Ychou, Emmanuelle Samalin, Guillaume Belthier, Fanny Grillet, Frédéric Hollande, Jihane Vitre-Boubaker, Matthieu Merlot, Julie Pannequin, Nicola Aceto, Jean-Marc Pascussi, Françoise Macari-Fine, François Bertucci, Diana Heaug-Wane, Fabienne Portales, Ilona Krol, Christophe Duperray, Jean-Christophe Boyer
Publikováno v:
Cancers
Cancers, MDPI, 2021, 13 (19), pp.4966. ⟨10.3390/cancers13194966⟩
Cancers; Volume 13; Issue 19; Pages: 4966
Cancers, 2021, 13 (19), pp.4966. ⟨10.3390/cancers13194966⟩
Cancers, Vol 13, Iss 4966, p 4966 (2021)
Cancers, 13 (19)
Cancers, MDPI, 2021, 13 (19), pp.4966. ⟨10.3390/cancers13194966⟩
Cancers; Volume 13; Issue 19; Pages: 4966
Cancers, 2021, 13 (19), pp.4966. ⟨10.3390/cancers13194966⟩
Cancers, Vol 13, Iss 4966, p 4966 (2021)
Cancers, 13 (19)
Simple Summary In the present work, we describe (for the first time) the use of the transmembrane protein, CD44v6, to detect CTCs from blood samples of several patients with colorectal or breast cancer. We used CD44v6 antibodies to demonstrate that l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c514241b09c42e5dc62f4a86bbc1eb5
https://hal.archives-ouvertes.fr/hal-03394453/document
https://hal.archives-ouvertes.fr/hal-03394453/document
Autor:
Olivier Bouché, Marie-Christine Etienne-Grimaldi, Karine Le Malicot, Jean-Christophe Boyer, Jean-François Seitz, Joseph Ciccolini, Jean-Louis Legoux, Thierry André, Marie-Anne Loriot, Chantal Barin-Le-Guellec, Joël Guigay, Pierre Michel, Fabienne Thomas, David Malka, Paolo Carni, Juliette Thariat, Fadil Masskouri, Roger Faroux, Suzette Delaloge
Publikováno v:
Bulletin du Cancer. 106:759-775
Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of early severe toxicities induced by fluoropyrimidines (FP). The French Group of Clinical Oncopharmacology (GPCO)-Unicancer and the French Pharmacogenetics Network (RNPGx) initiated
Autor:
Hélène Blons, Etienne Rouleau, Nathanaël Charrier, Gilles Chatellier, Jean-François Côté, Jean-Christophe Pages, Florence de Fraipont, Jean-Christophe Boyer, Jean Philippe Merlio, Alain Morel, Marie-Claude Gorisse, Patricia de Cremoux, Karen Leroy, Gérard Milano, L'houcine Ouafik, Jean-Louis Merlin, Delphine Le Corre, Pascaline Aucouturier, Jean-Christophe Sabourin, Frédérique Nowak, Thierry Frebourg, Jean-François Emile, Isabelle Durand-Zaleski, Pierre Laurent-Puig, MOKAECM Collaborative Group
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68945 (2013)
Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has e
Externí odkaz:
https://doaj.org/article/3b65b4d3c5ad41389ac86765d6d524f5